Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

L-Cycloserine

Generic Name: L-Cycloserine

Brand Names: Seromycin

Drug Type: Small Molecule

Chemical Formula: C_₃H_₆N_₂O_₂

CAS Number: 339-72-0

Unique Ingredient Identifier: AK7DRB7FMO

Overview

Antibiotic substance produced by Streptomyces garyphalus.

Background

Antibiotic substance produced by Streptomyces garyphalus.

Indication

本品与其他抗结核药联合，用于经一线药物（如吡嗪酰胺、链霉素、异烟肼、利福平和乙胺丁醇）治疗失败的患者。本品还可用于治疗非结核分枝杆菌感染如鸟复合分枝杆菌病的治疗。

Associated Conditions

Pulmonary Tuberculosis (TB)
Tuberculosis, Extrapulmonary
Grade 1, grade 2, grade 3, grade 4 Urinary Tract Infection

Clinical Trials

NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis

Phase 2

Not yet recruiting

Posted: 2023/11/13

Sponsor:NeuroRx, Inc.

ID:NCT06128213

iTBS+D-Cycloserine for Youth Suicide

Phase 2

Recruiting

Posted: 2023/11/07

Sponsor:University of Calgar...

ID:NCT06121284

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Phase 3

Active, not recruiting

Posted: 2023/10/13

Sponsor:

Beijing Chest Hospit...

ID:NCT06081361

Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine

Phase 2

Recruiting

Posted: 2023/08/16

Sponsor:Rose Research Center...

ID:NCT05994703

D-Cycloserine+iTBS PK Study

Phase 1

Completed

Posted: 2023/02/16

Sponsor:University of Calgar...

ID:NCT05731323

FDA Approved Products

SEROMYCIN

Manufacturer:Parsolex Gmp Center, Inc.

Route:ORAL

Strength:250 mg in 250 mg

Approved: 2023/01/19

NDC:13845-1200

Cycloserine

Manufacturer:Dr. Reddy’s Laboratories, Inc.

Route:ORAL

Strength:250 mg in 1 1

Approved: 2023/02/13

NDC:43598-235

Cycloserine

Manufacturer:Parsolex Gmp Center, Inc.

Route:ORAL

Strength:250 mg in 1 1

Approved: 2023/01/19

NDC:13845-1202

Seromycin

Manufacturer:Parsolex Gmp Center, Inc.

Route:ORAL

Strength:250 mg in 1 1

Approved: 2023/01/19

NDC:13845-1203

CYCLOSERINE

Manufacturer:Parsolex Gmp Center, Inc.

Route:ORAL

Strength:250 mg in 250 mg

Approved: 2023/01/19

NDC:13845-1201

Singapore Approved Products

No Singapore products found for this drug

Related News

Bipolar Depression Market Set to Grow Through 2034 with New Therapies in Pipeline

2 months ago

The global bipolar depression market is projected to experience significant growth through 2034, driven by increasing prevalence, with the United States accounting for approximately 85% of the market share across major regions.

Datopotamab Deruxtecan's Role in HR+/HER2- Breast Cancer Treatment: Sequencing and Safety Considerations

4 months ago

Datopotamab deruxtecan (Dato-DXd) is poised to become a standard treatment for metastatic hormone receptor-positive, HER2-negative breast cancer after prior systemic therapy.

Zymeworks Announces Strategic Priorities and Pipeline Expansion for 2025-2026

4 months ago

Zymeworks is set to advance ZW171 and ZW191 in Phase 1 trials for solid tumors, part of their '5 by 5' R&D program.

HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute as Flagship for Global Interventional Psychiatry Network

5 months ago

NRx Pharmaceuticals subsidiary HOPE Therapeutics announces planned acquisition of Kadima Neuropsychiatry Institute to serve as the flagship for an international network of interventional psychiatry clinics treating depression and PTSD.

NRx Pharmaceuticals Submits NDA Section to FDA for NRX-100 (Ketamine) in Suicidal Depression

5 months ago

NRx Pharmaceuticals has filed the initial section of its New Drug Application (NDA) to the FDA for NRX-100 (ketamine) to treat suicidal depression.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy